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Hepcidin Plays a Key Role in 6-OHDA Induced Iron Overload and
Apoptotic Cell Death in a Cell Culture Model of Parkinson’s Disease
Abstract
Background. Elevated brain iron levels have been implicated in the pathogenesis of Parkinson’s disease (PD).
However, the precise mechanism underlying abnormal iron accumulation in PD is not clear. Hepcidin, a
hormone primarily produced by hepatocytes, acts as a key regulator in both systemic and cellular iron
homeostasis. Objective. We investigated the role of hepcidin in 6-hydroxydopamine (6-OHDA) induced
apoptosis in a cell culture model of PD. Methods. We downregulated hepcidin using siRNA interference in
N27 dopaminergic neuronal cells and made a comparison with control siRNA transfected cells to investigate
the role of hepcidin in 6-OHDA induced neurodegeneration. Results. Hepcidin knockdown (32.3%,
P<0.0001) upregulated ferroportin 1 expression and significantly (P<0.05) decreased intracellular iron by
25%. Hepcidin knockdown also reduced 6-OHDA induced caspase-3 activity by 42% (P<0.05) and DNA
fragmentation by 29% (P=0.086) and increased cell viability by 22% (P<0.05). In addition, hepcidin
knockdown significantly attenuated 6-OHDA induced protein carbonyls by 52% (P<0.05) and intracellular
iron by 28% (P<0.01), indicating the role of hepcidin in oxidative stress. Conclusions. Our results
demonstrate that hepcidin knockdown protected N27 cells from 6-OHDA induced apoptosis and that
hepcidin plays a major role in reducing cellular iron burden and oxidative damage by possibly regulating
cellular iron export mediated by ferroportin 1.
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Background. Elevated brain iron levels have been implicated in the pathogenesis of Parkinson’s disease (PD). However, the precise
mechanism underlying abnormal iron accumulation in PD is not clear. Hepcidin, a hormone primarily produced by hepatocytes,
acts as a key regulator in both systemic and cellular iron homeostasis. Objective. We investigated the role of hepcidin in 6-
hydroxydopamine (6-OHDA) induced apoptosis in a cell culture model of PD.Methods. We downregulated hepcidin using siRNA
interference inN27 dopaminergic neuronal cells andmade a comparison with control siRNA transfected cells to investigate the role
of hepcidin in 6-OHDA induced neurodegeneration. Results. Hepcidin knockdown (32.3%, 𝑃 < 0.0001) upregulated ferroportin 1
expression and significantly (𝑃 < 0.05) decreased intracellular iron by 25%. Hepcidin knockdown also reduced 6-OHDA induced
caspase-3 activity by 42% (𝑃 < 0.05) and DNA fragmentation by 29% (𝑃 = 0.086) and increased cell viability by 22% (𝑃 < 0.05).
In addition, hepcidin knockdown significantly attenuated 6-OHDA induced protein carbonyls by 52% (𝑃 < 0.05) and intracellular
iron by 28% (𝑃 < 0.01), indicating the role of hepcidin in oxidative stress. Conclusions. Our results demonstrate that hepcidin
knockdown protected N27 cells from 6-OHDA induced apoptosis and that hepcidin plays a major role in reducing cellular iron
burden and oxidative damage by possibly regulating cellular iron export mediated by ferroportin 1.
1. Introduction
Parkinson’s disease (PD) is an incurable neurodegenerative
disease that affects more than 1% of people over 65 years
old and approximately 4% of the population aged over 80
years [1]. The prevalence is expected to rise sharply within
the next two decades because of progressive aging population
[2]. Parkinson’s disease is characterized by the progressive
loss of dopaminergic neurons in the substantia nigra (SN),
degeneration of projecting nerve fibers in the striatum, and
accumulation of intracytoplasmic inclusions, known as Lewy
bodies [3]. Although the etiology of PD is not clear, both
genetic and environmental risk factors including exposure to
metals and pesticides are considered to be involved in PD [4].
Iron, the most abundant trace metal in the brain, is
thought to play an important role in the pathogenesis of
PD. Studies have demonstrated the association between iron
dysregulation and PD. Increased levels of iron deposits in
the SN are observed in postmortem studies [5], as well
as in 6-hydroxydopamine (6-OHDA) [6] and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) [7] induced PD
animalmodels.The imaging studies of living PD patients also
confirmed the presence of accumulation of iron in the SN and
linked the extent of iron deposits to the severity of disease
[8]. Although iron is important in various physiological
functions, such as DNA synthesis, mitochondrial respiration,
and oxygen transport [9], free iron is potentially toxic as
it is involved in the generation of hydroxyl radicals, which
can react with lipid, protein, and DNA, leading to subse-
quent neuronal damage and death. Moreover, free iron in
dopaminergic neurons can accelerate toxic alpha-synuclein
fibril formation, leading to neuronal dysfunction [10].
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Because of the potential toxicity of iron, iron homeostasis
is tightly regulated by a complex system that coordinates iron
uptake, release, storage, and utilization. For example, iron is
delivered to tissues by circulating transferrin, and excess iron
in the cell is stored in the cytosolic ferritin [11]. Hepcidin
is a small peptide that is mainly secreted by hepatocytes
in response to inflammation, iron overload, and oxidative
stress [12, 13]. It controls systemic iron levels by regulating
iron absorption from the intestine, the release of iron from
degraded hemoglobin from macrophages, and stored iron
from hepatocyte [14]. Hepcidin is also considered as a master
regulator in the management of cellular iron homeostasis by
binding to iron exporter protein ferroportin 1 (Fpn1) in cell
membranes and causing its subsequent internalization and
lysosomal degradation [3]. Although hepcidin is predomi-
nantly expressed in the liver, recent research demonstrates
that hepcidin is also widely distributed in the central nervous
system. One study showed that hepcidin mRNA level is
increased with aging in mouse brain, particularly in the
cerebral cortex, hippocampus, and striatum, which leads to
decreased level of Fpn1 and the associated iron accumulation
in aging brain [15]. Another study showed that peripheral
iron overload induces hepcidin and decreased level of Fpn1
in the SN of rats, suggesting the critical role that hepcidin
plays in brain iron disturbance [16].Theobjective of this study
was to determine the role of hepcidin in 6-OHDA induced
cell death by knocking down hepcidin expression in N27
dopaminergic cell model of PD.
2. Materials and Methods
2.1. Chemicals. The immortalized rat mesencephalic dopam-
inergic neuronal cell line (1RB3AN27, generally referred to as
N27) was a kind gift from Dr. Kedar N. Prasad, University
of Colorado Health Sciences Center (Denver, CO). RPMI-
1640 medium, fetal bovine serum, L-glutamine, penicillin,
and streptomycin were obtained from Invitrogen (Carlsbad,
CA). Calcein-AM, ascorbic acid, mouse 𝛽-actin antibody, 6-
OHDA, ferrous sulfate, and ascorbic acid were purchased
from Sigma-Aldrich (St. Louis, MO). The Amaxa Nucleo-
fector kit was purchased from Lonza (Allendale, NJ). The
Absolutely RNA Miniprep kit and High Capacity cDNA
Archive kit were purchased from Stratagene (La Jolla, CA)
and Life Technologies (Grand Island, NY), respectively.
The hepcidin specific siRNA and scrambled siRNA were
purchased from Integrated DNA Technologies (Coralville,
IA). Substrate for caspase-3, acetyl-Asp-Glu-Val-Asp-AFC,
was obtained from MP Biomedicals (Solon, OH). The Cell
Death Detection ELISA Plus kit was purchased from Roche
Diagnostics (Indianapolis, IN). Protein Carbonyls Colori-
metric Assay kit was purchased from Cayman Chemical
(Ann Arbor, MI). The rabbit polyclonal antibody for Fpn1
was purchased from Alpha Diagnostic (San Antonio, TX).
Alexa Fluor 680 conjugated anti-mouse IgG and IR-dye 800
conjugated anti-rabbit IgG were purchased from Invitro-
gen (Carlsbad, CA) and Rockland Inc. (Gilbertsville, PA),
respectively. All solutions were prepared fresh prior to each
assay.
2.2. Cell Culture. N27 cells were grown in RPMI-1640
medium containing 10% fetal bovine serum, 2mmol/L L-
glutamine, 50 units of penicillin, and 50𝜇g/mL streptomycin
and maintained at 37∘C in a humidified atmosphere contain-
ing 5% CO
2
, as described in our previous publication [17].
2.3. Transient Transfections and Treatment Paradigm. N27
cells were transfected with hepcidin specific siRNA (hep-
cidin siRNA) or scrambled siRNA (control siRNA) using
the Amaxa Nucleofector kit, following the manufacturer’s
instructions. Briefly, 3 × 106 cells were resuspended in 100𝜇L
of the Nucleofector solution, along with 1.5 𝜇g of hepcidin
siRNA or control siRNA, and subsequently subjected to elec-
troporation using the Nucleofector program number A23.
After 72 hours of initial transfection, cells were harvested and
hepcidin mRNA was analyzed using quantitative real-time
RT-PCR to confirm the knockdown efficiency. To evaluate the
effect of hepcidin knockdown on 6-OHDA induced neuro-
toxicity, both control siRNA and hepcidin siRNA transfected
cells were plated for 48 hours and treated with or without
100 𝜇M 6-OHDA for 6 hours. Cells were collected at the end
of each treatment for the following experiments.
2.4. Quantitative Real-Time RT-PCR. Total RNAwas isolated
and converted to cDNA using the Absolutely RNAMiniprep
kit and High Capacity cDNA Archive kit, respectively. Real-
time PCRwas performed using a Brilliant SYBRGreenQPCR
Master Mix kit and theMx3000P QPCR system, as described
in our previous publication [18]. The 18s rRNA was used as
an internal control for quantifying RNA with the primer set
purchased from SABiosciences (Valencia, CA). The reaction
mixture included 2𝜇L of cDNA, 12.5 𝜇L of 2xmastermix, and
0.2 𝜇mol/L of each primer. Cycling conditions contained ini-
tial denaturation at 95∘C for 10min, followed by 40 cycles of
denaturation at 95∘C for 15 s and annealing at 60∘C for 10min.
Fluorescence was detected during the annealing/extension
step of each cycle. Dissociation curves were run to verify the
singularity of the PCRproducts.Thedatawere analyzed using
the comparative threshold cycle method as described in our
previous publication [18].
2.5. Western Blot Assay for Fpn1. Cell lysates were prepared
using a modified radio immunoprecipitation assay (RIPA)
buffer as described previously [19]. Equal amounts of protein
were loaded for each sample and separated on 12% SDS-
PAGE gels. After separation, the proteins were transferred
onto a nitrocellulose membrane and were incubated with
the rabbit polyclonal antibody directed against Fpn1 (1 : 1000)
and developed with IR-dye 800 anti-rabbit secondary anti-
body (1 : 5000). 𝛽-actin was used as the loading control.
Membranes were visualized on an Odyssey Infrared Imaging
system (LICOR, Lincoln, NE).
2.6. Calcein Quenching to Measure Intracellular Iron Levels.
The intracellular iron levels were determined by a calcein
fluorescence quenching method modified from a previous
study [20]. Calcein-AM is a membrane permeable, nonflu-
orescent molecule that becomes fluorescent by intracellular
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esterases. It is quenched rapidly by Fe2+ or Fe3+ and is a
good indicator of the labile iron pool [20], which is cellular
free iron or cheatable iron. The degree of quenching gives an
estimate of the amounts of cellular cheatable iron. After the
treatment, cells were incubated with calcein-AM in HEPES-
buffered saline (HBS) for 30min at 37∘C. The excess calcein
on the cell surface was washed off three times with HBS,
and fluorescence was recorded using a Synergy II microplate
reader (BioTek Instruments, Winooski, VT) at 485 nm exci-
tation and 530 nm emission. Change in fluorescence intensity
(with and without treatment after normalizing to protein
concentrations) reflected the intracellular iron levels. Calcein
fluorescence pictures were obtained with FLoid Cell Imag-
ing Station (Life Technologies).
2.7. Cell Viability Assays. Cell viability was measured using
MTT assay as described earlier [17]. After each treatment,
cells were incubated with serum-free RPMI medium con-
taining 0.25mg/mL MTT solution for 3 h at 37∘C, followed
by adding isopropanol-HCl (200 𝜇L) solution to dissolve
intracellular purple formazan. The absorbance was read at
570 nm with a reference wavelength of 630 nm using a
microplate reader (Molecular Devices, Sunnyvale, CA).
2.8. Caspase-3 Activity Assays. Caspase-3 activity was mea-
sured as described previously [21]. After treatment, the cell
pellet after centrifugationwas lysedwithTris buffer (50mol/L
Tris-HCl, 1mmol/L EDTA, and 10mmol/L EGTA at pH= 7.4)
containing 10 𝜇mol/L digitonin for 20min at 37∘C. Lysates
were subjected to quick centrifugation at 14,000×g and then
incubated with a specific fluorescent substrate (Ac-DEVD-
AFC, 50 𝜇mol/L) for 1 h at 37∘C. The caspase-3 activity was
measured with excitation at 400 nm and emission at 505 nm
using a fluorescencemicroplate reader.The caspase-3 activity
was expressed as fluorescent units/mg protein.
2.9. DNA Fragmentation Assays. DNA fragmentation assays
were performed using the Cell Death Detection ELISA Plus
kit as described previously [19]. After treatment, cell pellet
was incubated with lysis buffer provided in the kit.The lysates
were then centrifuged and the supernatant was incubated for
2 h with the mixture of HRP-conjugated antibody cocktail
that recognizes histones and single- and double-stranded
DNA. After washing away the unbound components, mea-
surements were made at 490 nm and 405 nm using a fluores-
cence microplate reader. DNA fragmentation was expressed
as absorbance units/mg protein.
2.10. Protein Carbonyl Assays. The oxidative damage to pro-
teins was determined by measuring the protein carbonyl
residues using DNPH (2,4-dinitrophenylhydrazine) accord-
ing to themanufacturer’s protocol. DNPH reacts with protein
carbonyls to produce the corresponding hydrazones, which
was measured spectrophotometrically at the wavelength of
360 nm. The carbonyl content was determined from the
differences in absorbance between DNPH-reacted samples
and nonreacted HCl samples and then standardized against
the protein concentrations in the samples.
2.11. Statistical Analysis. Datawere analyzed using theGraph-
Pad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA). All
values were expressed as mean ± SEM. Student’s 𝑡-test was
used to compare the differences between groups. The values
for two (control and hepcidin) siRNA transfected cells with
6-OHDA treatmentswere normalized to their respective con-
trols (without 6-OHDA treatment) before statistical analysis.
All the mean differences were considered significant at 𝑃 ≤
0.05.
3. Results
3.1. Downregulation of Hepcidin. To address the role of hep-
cidin in regulation of 6-OHDA inducedneurotoxicity, we first
utilized RNA interference (RNAi) technique to downregulate
hepcidin levels in N27 dopaminergic cells. As shown in
Figure 1(a), hepcidin mRNA levels were significantly down-
regulated (32.3%, 𝑃 < 0.0001) in hepcidin siRNA transfected
cells compared with control siRNA transfected cells. Since
hepcidin regulates Fpn1 by triggering its degradation, we fur-
ther determined whether downregulation of hepcidin leads
to increased Fpn1 protein expression (Figure 1(b)). Compared
to the control siRNA transfected cells, the Fpn1 protein levels
were elevated in hepcidin siRNA transfected cells, which
confirmed a negative relationship between hepcidin and
Fpn1 expression in dopaminergic cells. We also measured
intracellular iron, which was indirectly measured by cal-
cein fluorescence quenching, to ascertain whether decreased
expression of hepcidin and increased expression of Fpn1
reduced intracellular iron levels. Calcein is the most widely
adopted iron fluorescent probe that has been used tomonitor
changes of iron levels in a range of different cell types such
as hepatocytes and colon cells [22]. As shown in Figure 1(c),
hepcidin knockdown significantly decreased intracellular
iron by 25% (𝑃 < 0.05). To confirm calcein fluorescence
quenching by intracellular iron, we incubated the cells with
or without 1mM exogenous iron (ferrous sulfate in ascorbic
acid solution, 1 : 44 molar ratio, pH 6.0) for 30min and then
examined the calcein quenching by fluorescence microscopy.
As shown in Figure 1(d), supplementation of 1mM ferrous
sulfate effectively decreased calcein fluorescence.
3.2. Hepcidin Knockdown Protects N27 Cells from 6-OHDA
Induced Cytotoxicity. All the values in Figure 2 were pre-
sented as percentage of respective controls without 6-OHDA
treatment.We evaluated the effect of hepcidin knockdown on
6-OHDAmediated cell death usingMTT assay (Figure 2(a)).
Hepcidin knockdown moderately but significantly lessened
the toxic effect of 6-OHDA by increasing cell viability by
22% (𝑃 < 0.05). When apoptosis was measured, hepcidin
knockdown reduced 6-OHDA induced caspase-3 activity
significantly (Figure 2(b), 42%, 𝑃 < 0.05). DNA fragmenta-
tion was also reduced, but it was only marginally significant
(Figure 2(c), 𝑃 = 0.086). Together, these results demonstrate
that hepcidin knockdown protects against 6-OHDA induced
cell apoptosis.
3.3. Hepcidin Downregulation Reduces 6-OHDA Induced Pro-
tein Oxidative Damage and Intracellular Iron. As shown in
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Figure 1: Effect of hepcidin knockdown on hepcidin mRNA levels measured by quantitative real-time RT-PCR ((a), 𝑛 = 7-8), ferroportin
1 protein levels (normalized to 𝛽-actin) measured by Western blot (b), and intracellular iron measured by a calcein quenching method ((c),
𝑛 = 6) in N27 cells. Representative calcein fluorescence images with and without incubation of 1mM ferrous sulfate for 30min are shown (d).
Values are mean ± SEM. Differences between two groups were based on Student’s 𝑡-test; ∗𝑃 < 0.05; ∗∗𝑃 < 0.0001. Control siRNA: scrambled
small interfering RNA; hepcidin siRNA: hepcidin small interfering RNA; Fpn1: ferroportin 1.
Table 1: The role of hepcidin knockdown in 6-OHDA induced oxidative damage measured by protein carbonyls (𝑛 = 4) and intracellular
iron measured by calcein quenching method (𝑛 = 6).
Protein carbonyls (nmol/mg protein) Calcein quenching (fluorescent units/mg protein)
Control siRNA 18.5 ± 2.9 112.4 ± 4.8
Hepcidin siRNA 8.9 ± 1.1∗ 80.8 ± 6.2∗∗
Values are mean ± SEM; ∗𝑃 < 0.05; ∗∗𝑃 < 0.01. Differences between two groups were based on Student’s 𝑡-test; control siRNA: scrambled small interfering
RNA; hepcidin siRNA: hepcidin small interfering RNA.
Table 1, hepcidin knockdown decreased 6-OHDA induced
protein carbonyls by 52% (𝑃 < 0.05) and intracellular
iron by 28% (𝑃 < 0.01). These results show that hepcidin
knockdown might protect against 6-OHDA induced neu-
rotoxicity through attenuating oxidative stress by mediating
intracellular free iron.
4. Discussion
Iron is an essential nutrient and is involved in many func-
tions, such as acting as a cofactor for key enzymes involved in
neurotransmitter biosynthesis [23].On the other hand, excess
free iron can cause significant oxidative stress by involvement
in the production of hydroxyl radical formation, glutathione
consumption, protein aggregation, lipid peroxidation, and
nucleic acidmodification [24, 25].The body iron homeostasis
is regulated by iron regulatory proteins to minimize the
amount of free iron available to participate in free radical
formation. Among those proteins, hepcidin is considered as
a principal regulator because of its function to inhibit cellular
efflux of iron by binding to Fpn1 at the cell surface and
inducing its subsequent degradation [26].
Recent studies have suggested a critical role for hepcidin
in a variety of disorders, including anemia of inflammation,
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Figure 2:The role of hepcidin knockdown in 6-OHDA induced cytotoxicity measured by MTT ((a), 𝑛 = 6), caspase-3 activity ((b), 𝑛 = 4-5),
and DNA fragmentation ((c), 𝑛 = 4) in N27 cells. Cells were treated with 100𝜇M 6-OHDA for 6 hours and the values (mean ± SEM) are
normalized to their respective controls without 6-OHDA treatment; ∗𝑃 < 0.05; difference between two groups was based on Student’s 𝑡-test;
control siRNA: scrambled small interfering RNA; hepcidin siRNA: hepcidin small interfering RNA.
chronic kidney disease, and familial hemochromatosis [26–
28]. However, the participation of hepcidin in neurode-
generative disorders is very limited. In our earlier study
on cell culture [29], 6-OHDA increased the expression
of hepcidin and decreased the expression of Fpn1, which
made us design this current study to investigate the effect
of hepcidin with knockdown experiments. We used N27
dopaminergic neuronal cell model to detect hepcidin and
Fpn1 expression, sinceN27 cell line possesses all physiological
and biochemical properties of dopaminergic neurons [30].
Our results show that both hepcidin and Fpn1 are expressed
in N27 cells and that knockdown of hepcidin remarkably
increased Fpn1 expression and reduced intracellular iron
levels as measured by calcein quenching. These results are
consistent with previous studies, which demonstrate that
hepcidin is widely expressed in murine brain and might
play a key role in regulating iron levels in the brain by
downregulating Fpn1 expression [15, 31, 32].
Our study also shows that regulation of brain iron
efflux by hepcidin may play a protective role in 6-OHDA
induced neurotoxicity. Hepcidin knockdown and subsequent
upregulation of Fpn1 protein significantly attenuated the
protein oxidative damage induced by 6-OHDA, ultimately
leading to a reduction in cell apoptosis, as evidenced by
decreased caspase-3 activation and marginally decreasing
DNA fragmentation. Increasing caspase-3 activity and DNA
fragmentation, respectively, more than 2- and 1.5-fold in
the control siRNA cells but only showing a small increase
in hepcidin siRNA cells with 6-OHDA treatment clearly
shows the protection with hepcidin downregulation, even
with low knockdown efficiency. 6-OHDA is a hydroxylated
analogue of the neurotransmitter dopamine and represents
a classic neurotoxin used for the initiation of the PD neu-
rodegeneration both in vitro and in vivo [33]. Studies have
shown abnormal iron accumulation in 6-OHDA induced
PD models, and 6-OHDA induced neurotoxicity may result
6 Parkinson’s Disease
from free iron and the ensuing production of free radical
species [34]. However, the precise mechanism underlying
abnormal iron accumulation in 6-OHDA induced neurotox-
icity is not very clear. Song et al. [35] demonstrated that
upregulation of iron regulatory protein 1 (IRP1) might be
responsible for decreased expression of Fpn1 and increased
cellular iron accumulation. Another study reported that
divalent metal transporter 1 (DMT1) + IRE upregulation
is involved in 6-OHDA induced iron accumulation and
aggravated oxidative injury [36]. Our study provides direct
evidence for the first time that hepcidin-ferroportin axis at
least partially accounts for iron accumulation in 6-OHDA
induced neurodegeneration. Hepcidin knockdown resulted
in upregulation of Fpn1, which may enhance iron release
and alleviate iron accumulation in dopaminergic neurons,
and eventually protected neurons from 6-OHDA induced
apoptosis. Our data with calcein quenching support this
relationship. In addition to its role in iron homeostasis,
hepcidin is also recognized as a principal mediator in
inflammation [37, 38], which is also directly linked to the
pathogenesis of PD [39, 40]. Thus, further study is needed to
study the linkage between hepcidin expression, iron status,
and neuroinflammation in PD. In addition, research has
shown that 6-OHDA can induce oxidative damage and
neurotoxicity of both the peripheral and the central nervous
system [41], and hepcidin is strongly expressed in other brain
regions such as the olfactory bulb [42]. Future research is
needed to investigate whether hepcidin has a role in pro-
tecting from 6-OHDA induced neurotoxicity in other brain
regions.
5. Conclusions
In conclusion, our study demonstrates that hepcidin plays an
important role in iron accumulation, thus causing oxidative
stress and associated neurotoxicity. Hence, the approaches
that can reduce hepcidin and increase Fpn1 expression might
be effective strategies in preventing the progression of PD.
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